Article

Identification of ASF/SF2 as a Critical, Allele-Specific Effector of the Cyclin D1b Oncogene

Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, Ohio, USA.
Cancer Research (Impact Factor: 9.28). 05/2010; 70(10):3975-84. DOI: 10.1158/0008-5472.CAN-09-3468
Source: PubMed

ABSTRACT The cyclin D1b oncogene arises from alternative splicing of the CCND1 transcript, and harbors markedly enhanced oncogenic functions not shared by full-length cyclin D1 (cyclin D1a). Recent studies showed that cyclin D1b is selectively induced in a subset of tissues as a function of tumorigenesis; however, the underlying mechanism(s) that control tumor-specific cyclin D1b induction remain unsolved. Here, we identify the RNA-binding protein ASF/SF2 as a critical, allele-specific, disease-relevant effector of cyclin D1b production. Initially, it was observed that SF2 associates with cyclin D1b mRNA (transcript-b) in minigene analyses and with endogenous transcript in prostate cancer (PCa) cells. SF2 association was altered by the CCND1 G/A870 polymorphism, which resides in the splice donor site controlling transcript-b production. This finding was significant, as the A870 allele promotes cyclin D1b in benign prostate tissue, but in primary PCa, cyclin D1b production is independent of A870 status. Data herein provide a basis for this disparity, as tumor-associated induction of SF2 predominantly results in binding to and accumulation of G870-derived transcript-b. Finally, the relevance of SF2 function was established, as SF2 strongly correlated with cyclin D1b (but not cyclin D1a) in human PCa. Together, these studies identify a novel mechanism by which cyclin D1b is induced in cancer, and reveal significant evidence of a factor that cooperates with a risk-associated polymorphism to alter cyclin D1 isoform production. Identification of SF2 as a disease-relevant effector of cyclin D1b provides a basis for future studies designed to suppress the oncogenic alternative splicing event.

Download full-text

Full-text

Available from: Michael A Augello, Dec 17, 2013
0 Followers
 · 
117 Views
  • Source
    • "Which of these factors contribute to the regulation of BCL-X splicing in PCa cells is still largely unknown. SRSF1 [24] and SAM68 [45] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer (PCa) remains one of the most frequent causes of death for cancer in the male population. Although the initial antiandrogenic therapies are efficacious, PCa often evolves into a hormone-resistant, incurable disease. The genetic and phenotypic heterogeneity of this type of cancer renders its diagnosis and cure particularly challenging. Mounting evidence indicates that alternative splicing, the process that allows production of multiple mRNA variants from each gene, contributes to the heterogeneity of the disease. Key genes for the biology of normal and neoplastic prostate cells, such as those encoding for the androgen receptor and cyclin D1, are alternatively spliced to yield protein isoforms with different or even opposing functions. This review illustrates some examples of genes whose alternative splicing regulation is relevant to PCa biology and discusses the possibility to exploit alternative splicing regulation as a novel tool for prognosis, diagnosis, and therapeutic approaches to PCa.
    International Journal of Cell Biology 08/2013; 2013(1):458727. DOI:10.1155/2013/458727
  • Source
    • "Introduction of the RD domain allows for separation of the cyclin D1 cdk4-modulatory and ARmodulatory functions, and leads to not only suppression of AR-dependent cell growth but also triggers loss of cell viability, thus illustrating the importance of cyclin D1 on cellular outcomes (Schiewer et al., 2009). As will be discussed below, the ability of cyclin D1 to dampen AR activity appears to be altered in prostate cancer, as mediated by downregulation of cyclin D1 expression, mislocalization, and/or a shift to production of the cyclin D1b variant, which is compromised for AR-regulatory functions (Burd et al., 2006; Comstock et al., 2009, 2007; Knudsen, 2006; Olshavsky et al., 2010). As would be expected based on conservation of the RD domain, cyclin D3 elicits similar functions with regard to AR control (Olshavsky et al., 2008); in addition, cdk11-mediated functions of cyclin D3 also contribute to negative regulation of AR (Zong et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer cells are exquisitely dependent on androgen receptor (AR) activity for proliferation and survival. As these functions are critical targets of therapeutic intervention for human disease, it is imperative to delineate the mechanisms by which AR engages the cell cycle engine. More than a decade of research has revealed that elegant intercommunication between AR and the cell cycle machinery governs receptor-dependent cellular proliferation, and that perturbations in this process occur frequently in human disease. Here, AR-cell cycle interplay and associated cancer relevance will be reviewed.
    Molecular and Cellular Endocrinology 07/2011; 352(1-2):34-45. DOI:10.1016/j.mce.2011.06.033 · 4.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A workshop addressing regulation of clinical implementation of stem cell therapies preceded the ISSCR 8th Annual Meeting, cosponsored by the International Society for Stem Cell Research, the California Institute for Regenerative Medicine and the International Society for Cellular Therapy.
    Cell stem cell 10/2010; 7(4):451-4. DOI:10.1016/j.stem.2010.09.004 · 22.15 Impact Factor
Show more